PRDX5 and ovarian endometrioid adenocarcinoma: Furthermore, PRDX5 also predicted poor PFS for all ovarian cancer patients, endometrioid ovarian cancer patients, grade II ovarian cancer patients, and stages III and IV ovarian cancer patients.